Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

Pushkar et al., NCT04542694, Nov 2020
Late treatmentRCT · 200 patients · Russia
Favipiravir for COVID-19
Pushkar et al. NCT04542694 · November 2020
RCT 200 patients showing improvements in clinical recovery and viral clearance with favipiravir. There is no paper available but results are posted in clinicaltrials.gov.
Potential risks of favipiravir include kidney injury1-3, liver injury2-5, cardiovascular events5,6, pulmonary toxicity6,7, and mutagenicity, carcinogenicity, teratogenicity, embryotoxicity, and the creation of dangerous variants8-14.
OutcomeImprovementEffect · pTreatmentControl
risk of no clinical status improvement of 2+ WHO-OSCI at ~10 days 14.1% lower · RR 0.86 · p = 0.06 14.1% lowerRR 0.86p = 0.06 73 of 100 (73.0%) 85 of 100 (85.0%) treatment 73 of 100 (73.0%), control 85 of 100 (85.0%)NNT 8.3
relative time to clinical improvement 33.3% lower · relative time 0.67 · p < 0.0001*** 33.3% lowerrelative time 0.67p < 0.0001*** 100 100 treatment 100, control 100
risk of no fever reduction by day 3 45.2% lower · RR 0.55 · p < 0.001*** 45.2% lowerRR 0.55p < 0.001*** 40 of 100 (40.0%) 73 of 100 (73.0%) treatment 40 of 100 (40.0%), control 73 of 100 (73.0%)NNT 3.0
relative time to resolution of fever 20.0% lower · relative time 0.80 · p = 0.05 20.0% lowerrelative time 0.80p = 0.05 100 100 treatment 100, control 100
risk of no discharge at day 10 69.7% lower · RR 0.30 · p < 0.001*** 69.7% lowerRR 0.30p < 0.001*** 10 of 100 (10.0%) 33 of 100 (33.0%) treatment 10 of 100 (10.0%), control 33 of 100 (33.0%)NNT 4.3
risk of no full recovery at day 10 26.7% lower · RR 0.73 · p < 0.001*** 26.7% lowerRR 0.73p < 0.001*** 66 of 100 (66.0%) 90 of 100 (90.0%) treatment 66 of 100 (66.0%), control 90 of 100 (90.0%)NNT 4.2
risk of no improvement in lung CT 33.3% lower · RR 0.67 · p = 0.007** 33.3% lowerRR 0.67p = 0.007** 40 of 100 (40.0%) 60 of 100 (60.0%) treatment 40 of 100 (40.0%), control 60 of 100 (60.0%)NNT 5.0
risk of no viral clearance 90.5% lower · RR 0.10 · p < 0.001*** 90.5% lowerRR 0.10p < 0.001*** 2 of 100 (2.0%) 21 of 100 (21.0%) treatment 2 of 100 (2.0%), control 21 of 100 (21.0%)NNT 5.3

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. ** p < 0.01   *** p < 0.001

Pushkar et al., 5 Nov 2020, Randomized Controlled Trial, Russia, preprint, mean age 50.0, 1 author.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 Russia Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia Russia favored low-cost treatments.The average efficacy of treatments was moderate.Low-cost treatments improve early treatment, andprovide complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 Russia Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Dominican Rep. Bolivia Côte d'Ivoire Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Zimbabwe Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Russia favored low-cost treatments.The average efficacy was moderate.Low-cost protocols improve early treatment,and add complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Late treatment
is less effective